HPC
INO icon

HM Payson & Co’s Inovio Pharmaceuticals INO Stock Holding History

HM Payson & Co’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2
Closed -$4 – 1163
2026
Q1 		$4 Buy
+2
New +$3 ﹤0.01% 1125
2020
Q4 		– Sell
-6
Closed -$1K – 1124
2020
Q3 		$1K Buy
6
+5
+500% +$1.04K ﹤0.01% 997
2020
Q2 		$0 Buy
+1
New +$161 ﹤0.01% 891

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

HM Payson & Co's INO Position: Q2 2026 in Review

HM Payson & Co sold out of Inovio Pharmaceuticals (INO) in Q2 2026, closing a stake of 2 shares — an estimated $4 sold.

HM Payson & Co first reported a position in INO in Q2 2020 and held it in 3 quarters. The position peaked at $1K in Q3 2020. 103 funds tracked by Wall St. Rank hold INO as of Q2 2026.

  • HM Payson & Co reported no remaining Inovio Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • HM Payson & Co sold 2 Inovio Pharmaceuticals shares in Q2 2026, an estimated $4.
  • HM Payson & Co first reported a position in Inovio Pharmaceuticals in Q2 2020 and held it in 3 quarters.
  • HM Payson & Co's Inovio Pharmaceuticals position peaked at $1K in Q3 2020.
  • 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on HM Payson & Co's 13F filing for Q2 2026, filed 17 Jul 2026.